These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19884628)

  • 1. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
    Boers M
    Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of biologics in early rheumatoid arthritis.
    Finckh A; Bansback N; Liang MH
    Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
    Pressman Lovinger S
    JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
    [No Abstract]   [Full Text] [Related]  

  • 6. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
    van den Hout WB
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 10. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
    Bansback NJ; Young A; Brennan A
    Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
    Tsutani K; Igarashi A
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis: out of touch with clinical reality?
    Maetzel A
    Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
    [No Abstract]   [Full Text] [Related]  

  • 13. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatments for rheumatoid arthritis.
    Kavanaugh A
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):4-7. PubMed ID: 17491580
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
    Saraux A; Gossec L; Goupille P; Bregman B; Boccard E; Dupont D; Beresniak A
    Rheumatology (Oxford); 2010 Apr; 49(4):733-40. PubMed ID: 20081224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing model structures in cost-effectiveness analysis.
    Russell LB
    Med Decis Making; 2005; 25(5):485-6. PubMed ID: 16160203
    [No Abstract]   [Full Text] [Related]  

  • 19. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A; Koenig AS; Bananis E; Singh A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.
    O'Dell JR
    Arthritis Rheum; 2007 Dec; 56(12):3884-6. PubMed ID: 18050217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.